This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
BDX Launches AI-Enabled Platform to Unify Healthcare Connectivity
by Zacks Equity Research
BD's new AI-driven Incada Platform and upgraded Pyxis Pro system unite connected care, driving its digital healthcare edge.
BDXPositive Net Change MASIPositive Net Change MMSIPositive Net Change WSTNegative Net Change
medical medical-devices
The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies
by Zacks Equity Research
Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.
AZNPositive Net Change AMATPositive Net Change PKENegative Net Change NTWKPositive Net Change RTXPositive Net Change
aerospace computers medical semiconductor
Top Research Reports for AstraZeneca, RTX & Applied Materials
by Mark Vickery
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
AZNPositive Net Change LHNegative Net Change RSGNegative Net Change AMATPositive Net Change EMEPositive Net Change PKENegative Net Change NTWKPositive Net Change RTXPositive Net Change
aerospace computers medical semiconductor
Zacks.com featured highlights include Stryker, NVIDIA, ResMed and Ralph Lauren
by Zacks Equity Research
Zacks highlights four GARP (Growth at a Reasonable Price) stocks Stryker, NVIDIA, ResMed, and Ralph Lauren combining strong growth prospects with attractive valuations for maximum returns.
SYKPositive Net Change NVDAPositive Net Change RMDNegative Net Change RLPositive Net Change
consumer-discretionary medical semiconductor
Zacks.com featured highlights include Red Robin Gourmet Burgers, 10x Genomics, Norwegian Cruise Line, Electromed and Analog Devices
by Zacks Equity Research
Zacks spotlights five efficient stocks Red Robin, 10x Genomics, Norwegian Cruise Line, Electromed, and Analog Devices that excel in turning assets and operations into profits.
ADIPositive Net Change RRGBNegative Net Change ELMDPositive Net Change NCLHPositive Net Change TXGNegative Net Change
consumer-discretionary medical medical-devices restaurants semiconductor
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
by Ahan Chakraborty
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
by Zacks Equity Research
PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.
ILMNPositive Net Change QGENNegative Net Change PACBPositive Net Change TXGNegative Net Change
medical medical-devices
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms
by Zacks Equity Research
HealthEquity rolls out GLP-1 telehealth and direct HSA enrollment platforms, targeting affordability and growth amid rising healthcare costs and regulatory expansion.
CIPositive Net Change HQYNegative Net Change HIMSNegative Net Change LFMDNegative Net Change
medical medical-devices
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
by Urmimala Biswas
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
ABTPositive Net Change BSXPositive Net Change MDTPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices
Will Positive Regulatory Updates Further Boost INCY Stock?
by Zacks Equity Research
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
GSKPositive Net Change NVSNegative Net Change QGENNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval
by Zacks Equity Research
STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.
ISRGPositive Net Change STXSNegative Net Change MBOTNegative Net Change PRCTPositive Net Change
medical medical-devices
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
by Abhinab Dasgupta
Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.
GSPositive Net Change UNHPositive Net Change PSANegative Net Change MUPositive Net Change PEPPositive Net Change XOMANegative Net Change HCAPositive Net Change MNSTNegative Net Change NTLANegative Net Change OVIDNegative Net Change HTCRNegative Net Change
medical reit semiconductor
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
by Sridatri Sarkar
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
TXGNegative Net Change SOPHNegative Net Change TEMPositive Net Change
earnings medical
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology readies its Q3 report, with steady Clear Aligner demand and scanner upgrades expected to shape its performance.
ALGNPositive Net Change IDXXPositive Net Change ANIPNegative Net Change EXASNegative Net Change
earnings medical
Buy, Hold or Sell Hologic Stock? Key Insights Ahead of Q4 Earnings
by Moumi Mondal
HOLX's fiscal Q4 2025 earnings may face limits as macro pressures and slow Diagnostics curb momentum.
BSXPositive Net Change MDTPositive Net Change HOLXNegative Net Change
earnings medical medical-devices
Here's How IDEXX Laboratories is Placed Ahead of Q3 Earnings
by Zacks Equity Research
IDXX heads into Q3 earnings with steady estimates and strong momentum across its diagnostics and pet healthcare segments.
IDXXPositive Net Change ANIPNegative Net Change EXASNegative Net Change EHCPositive Net Change
earnings medical medical-devices
Avantor Partners With BlueWhale Bio to Advance CAR-T Manufacturing
by Zacks Equity Research
AVTR collaborates with BlueWhale Bio to speed CAR-T manufacturing using CDNP tech, aiming to scale production and expand patient access.
MASIPositive Net Change MMSIPositive Net Change WSTNegative Net Change AVTRNegative Net Change
medical medical-devices
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
by Zacks Equity Research
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
ANIPNegative Net Change ESPRPositive Net Change EVOPositive Net Change CMMBNegative Net Change
medical
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
by Zacks Equity Research
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
by Santanu Roy
From Red Robin to Analog Devices, these five high-efficiency stocks stand out for their strong ratios and surprise earnings potential.
ADIPositive Net Change RRGBNegative Net Change ELMDPositive Net Change NCLHPositive Net Change TXGNegative Net Change
consumer-discretionary medical medical-devices restaurants semiconductor
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
by Vasundhara Sawalka
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
SYKPositive Net Change NVDAPositive Net Change RMDNegative Net Change RLPositive Net Change
artificial-intelligence consumer-discretionary medical tech-stocks
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
DHR gears up for Q3 results with steady earnings estimates and mixed segment trends across Life Sciences, Biotechnology and Diagnostics.
DHRNegative Net Change CVSPositive Net Change TDOCNegative Net Change MEDPNegative Net Change
medical
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
by Sridatri Sarkar
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
DGXNegative Net Change GHNegative Net Change TEMPositive Net Change WHWKPositive Net Change
medical
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
by Sundeep Ganoria
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Intuitive Surgical Pre-Q3 Analysis: Buy, Hold or Sell ISRG Stock Now?
by Indrajit Bandyopadhyay
Intuitive Surgical enters Q3 earnings season on strong momentum, backed by robust procedure growth and da Vinci 5 adoption. However, tariff risks and global CapEx constraints remain challenges.
BSXPositive Net Change ISRGPositive Net Change TMONegative Net Change
medical medical-devices